Keybanc maintains Brixmor Property Group (NYSE:BRX) with a Overweight and raises the price target from $26 to $29.
B. Riley Securities Initiates Coverage On Rigel Pharmaceuticals with Neutral Rating, Announces Price Target of $4
B. Riley Securities analyst Kalpit Patel initiates coverage on Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral rating and announces Price Target of $4.